🔗 Share this article

As America proceeds with sweeping adjustments to its vaccination guidelines, an unexpected name has emerged in a surprising turn: Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines throughout the pandemic and has focused upon potential deaths after Covid immunization in her recent time at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Health officials had intended to reveal sweeping changes to the childhood immunization program in December, synchronizing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US at odds with many the international standard with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is listed to speak at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for halting certain childhood shot schedules in the US so as to align more like Denmark, a nation with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Background

Høeg has little discernible experience in pharmaceutical research, approval processes or administrative roles, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the CDER, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in leading a sizeable institution. She has no expertise in industry regulation.”

Former directors of the center would “understand laws and regulations and the underlying principles of drug development”, said Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that prior appointees who ran CBER have had.”

CDER has an immense portfolio at the agency, she stated.

“The public just pays attention on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and so forth, and all of those must be supervised,” she noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the role, which supervises in excess of 5,000 personnel. “It’s a massive leadership role, if you do it right,” she added.

Agency Reaction and Contentious Initiatives

Regarding concerns about Dr. Høeg's credentials and whether this assignment indicates increased cooperation among FDA leaders on vaccines, a press secretary responded that the “questions rely on incorrect presumptions”.

“This background is consistent with the responsibilities of her job,” the official said, citing the months Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's controversial priority voucher program, a disputed expedited medication authorization process that allegedly troubled her preceding directors. “By what process are these therapies being chosen for this fast-track system? Who makes the decisions?” Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, with the exception of vaccines.”

Established History on Immunizations

Regarding vaccines, Høeg has a more established, if concerning, history, critics said. She authored a study using non-validated volunteer-provided data to assess the incidence of heart inflammation after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the current federal leadership included altering regulations for recently developed shots and discontinuing “unnecessary” immunizations, she said after the election on a online show. At the agency, Dr. Høeg has according to sources suggested preventing young men from obtaining Covid vaccinations.

“She is an thorough dogmatist who commences with her beliefs and works backwards to fit the evidence in a highly disingenuous, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined other dissenters, {like|